May 02, 2023 / 06:00PM GMT
Doug Tsao - H.C. Wainwright & Co. - Analyst
(inaudible - microphone inaccessible) Okay. So welcome, everybody. I'm Doug Tsao, Senior Analyst at H.C. Wainwright. Thank you, everybody, for joining us.
We are pleased to have with us, Outlook Therapeutics, represented by the company's CEO Russ Trenary and the most recent addition, Glen Olsheim. And I don't -- I'm forgetting your title.
Glen Olsheim - Outlook Therapeutics, Inc. - Executive Director, Commercial Excellence
Executive Director of Commercial Excellence.
Questions and Answers:
Doug Tsao - H.C. Wainwright & Co. - AnalystExecutive Director of Commercial Excellence. So why don't -- Russ, maybe we start with just an introduction to Outlook, and what you're trying to accomplish because I think it's a little bit of a unique story if you will.
Russ Trenary - Outlook Therapeutics, Inc. - President & CEO
So I think big picture, we start with the fact that we're in the anti-VEGF space for retinal.
Trustpilot
